成都大学附属医院
Affiliated Hospital of Chengdu University
在本站收录的 53 种疾病中,这家医院列在其中 9 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
成都大学附属医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma7 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma30 篇牵头论文
- 胃癌Stomach cancer14 篇牵头论文
- 脊索瘤Chordoma1 篇牵头论文
- 骨肉瘤Osteosarcoma5 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis8 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis3 篇牵头论文
- 白塞病Behçet disease2 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文
未列出的收录疾病:食管鳞状细胞癌、肝母细胞瘤、视网膜母细胞瘤、胃肠道间质瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 5 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。
这些数字背后的记录
牵头的论文7
- Global, regional, and national epidemiology of nasopharyngeal carcinoma in middle-aged and elderly patients from 1990 to 2021.
- PD-1 inhibitor combined with TPF induction chemotherapy in locally advanced nasopharyngeal carcinoma: a retrospective study of efficacy and safety.
- Exploring the influence of age on the causes of death in advanced nasopharyngeal carcinoma patients undergoing chemoradiotherapy using machine learning methods.
- The efficacy of natural products for the treatment of nasopharyngeal carcinoma.
- Radiotherapy-Related Quality of Life in Nasopharyngeal Carcinoma Patients: A Systematic Review and Meta-Analysis.
- Randomised controlled trial of Jiandu granule in preventing chemoradiotherapy-induced oral mucositis.
- Hedyotis diffusae Herba-Andrographis Herba inhibits the cellular proliferation of nasopharyngeal carcinoma and triggers DNA damage through activation of p53 and p21.
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 30 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 5 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文30
- Prognostic significance of systemic immune-inflammation index in hepatocellular carcinoma: a meta-analysis.
- Comprehensive pan-cancer characterization of IRAK2 as a potential prognostic biomarker and therapeutic target with validation in hepatocellular carcinoma.
- The Efficacy and Safety of Anlotinib Combination Therapy for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
- RNF220 enhances USP22 to promote cell growth, metastasis and stemness in hepatocellular carcinoma by activating the Akt pathway.
- The role of PD‑1/PD‑L1 axis in liver diseases.
- Multidimensional analysis reveals the potential of ACSL3 as a cancer biomarker: from pan-cancer exploration to functional validation in hepatocellular carcinoma.
- Dihydroartemisinin: A Promising Therapeutic Agent Against the Hepatitis-to-Hepatocellular Carcinoma Cascade.
- Zuojin capsule improves T cell exhaustion and tumor immune microenvironment of hepatocellular carcinoma through the mTOR-eIF4E/p70S6K-CDK1 pathway.
- Crosstalk between exosomes and tumor-associated macrophages in hepatocellular carcinoma: implication for cancer progression and therapy.
- Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation.
- Establishment of a prognostic nomogram and risk stratification system for patients with distant-metastatic hepatocellular carcinoma: A population-based study.
- PCNP promotes hepatocellular carcinoma progression by upregulating UHRF2 to activate ErbB3/Ras/Raf pathway.
- A mitochondrial-related gene signature predicts prognosis and immunotherapy response in hepatocellular carcinoma.
- Establishment of a prognostic nomogram and risk stratification system for patients with combined hepatocellular-cholangiocarcinoma.
- Mitochondrial-Targeted CS@KET/P780 Nanoplatform for Site-Specific Delivery and High-Efficiency Cancer Immunotherapy in Hepatocellular Carcinoma.
- Study on the mechanism of quercetin in Sini Decoction Plus Ginseng Soup to inhibit liver cancer and HBV virus replication through CDK1.
- CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges.
- The current status and future of targeted-immune combination for hepatocellular carcinoma.
- Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis.
- Artesunate: A potential drug for the prevention and treatment from hepatitis to hepatocellular carcinoma.
- Expression of lipid-metabolism genes is correlated with immune microenvironment and predicts prognosis of hepatocellular carcinoma.
- Coptidis rhizoma and evodiae fructus against lipid droplet deposition in nonalcoholic fatty liver disease-related liver cancer by AKT.
- The current status and future of PD-L1 in liver cancer.
- MYB proto-oncogene like 2 promotes hepatocellular carcinoma growth and glycolysis via binding to the Optic atrophy 3 promoter and activating its expression.
- Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma.
- Long Noncoding RNA TUG1 Inhibits Tumor Progression through Regulating Siglec-15-Related Anti-Immune Activity in Hepatocellular Carcinoma.
- Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma.
- Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.
- miR-100 Suppresses the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma Cells via Targeting CXCR7.
- Tumor infiltrating lymphocytes associated competitive endogenous RNA networks as predictors of outcome in hepatic carcinoma based on WGCNA analysis.
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 5 家医院列在胃癌下全国有 218 家医院列在胃癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文14
- Comparative efficacy and safety of distinct PD-1 antibodies in unresectable advanced or recurrent gastric and gastroesophageal junction cancer: a network meta-analysis of randomized controlled trials.
- PET/MRI is superior to PET/CT in detecting oesophago and gastric carcinomas: a meta-analysis.
- Decoding inflammatory mediators in the Correa's cascade: From chronic gastritis to carcinogenesis and targeted therapies.
- Targeting ICAM1/ITGB2 with plumbagin preserves intercellular adhesion and attenuates gastric precancerous lesions.
- Natural products for gastric carcinoma prevention and treatment: Focus on their antioxidant stress actions in the Correa's cascade.
- Tanshinone I attenuates gastric precancerous lesions by inhibiting epithelial mesenchymal transition through the p38/STAT3 pathway.
- Gallic acid alleviates gastric precancerous lesions through inhibition of epithelial mesenchymal transition via Wnt/β-catenin signaling pathway.
- Phytochemicals and mitochondria: Therapeutic allies against gastric cancer.
- Ginsenoside Rg3 inhibits angiogenesis in gastric precancerous lesions through downregulation of Glut1 and Glut4.
- Berberine for gastric cancer prevention and treatment: Multi-step actions on the Correa's cascade underlie its therapeutic effects.
- Pull the plug: Anti-angiogenesis potential of natural products in gastrointestinal cancer therapy.
- circCOL1A1 Promotes the Progression of Gastric Cancer Cells through Sponging miR-145 to Enhance RABL3 Expression.
- TASP1 Promotes Proliferation and Migration in Gastric Cancer via EMT and AKT/P-AKT Pathway.
- Compare the Effects of Magnolol on Gastric Cancer Cells Through c-Jun N-Terminal Kinase Signaling Pathway and Gold Magnetic.
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 4 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 13 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文5
- MicroRNA-767-5p promotes metastasis but improves chemotherapeutic and radiotherapeutic sensitivity of osteosarcoma.
- Mechanism by which CAP regulates the "cold-heat" balance in osteosarcoma model mice: an integrative study of metabolomics, transcriptomics, and network pharmacology.
- KNTC1 knockdown inhibits the proliferation and migration of osteosarcoma cells by MCM2.
- The fibrinogen-albumin ratio as a novel prognostic factor for elderly patients with osteosarcoma.
- Inhibition of osteosarcoma cell proliferation in vitro and tumor growth in vivo in mice model by alstonine through AMPK-activation and PGC-1α/TFAM up-regulation.
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 16 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文8
- Effects of air pollutants on the incidence, progression, and mortality of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
- IGFBP7: A novel biomarker involved in a positive feedback loop with TGF-β1 in idiopathic pulmonary fibrosis.
- Aging-associated interleukin-11 drives the molecular mechanism and targeted therapy of idiopathic pulmonary fibrosis.
- Targeting the immunometabolism interface: A novel strategy for IPF therapy.
- Elucidating the causal associations and mechanisms between circulating immune cells and idiopathic pulmonary fibrosis: new insights from Mendelian randomization and transcriptomics.
- Buyang Huanwu decoction ameliorates bleomycin-induced pulmonary fibrosis in rats by attenuating the apoptosis of alveolar type II epithelial cells mediated by endoplasmic reticulum stress.
- Protective role of baicalin in the dynamic progression of lung injury to idiopathic pulmonary fibrosis: A meta-analysis.
- Exploring the role and mechanism of Astragalus membranaceus and radix paeoniae rubra in idiopathic pulmonary fibrosis through network pharmacology and experimental validation.
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 8 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
这些数字背后的记录
牵头的论文3
- Edaravone for patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.
- COVID-19 and the risk of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis.
- Meta-analysis of the association between CHCHD10 Pro34Ser variant and the risk of amyotrophic lateral sclerosis.
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 5 家医院列在白塞病下全国有 149 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
成都有 4 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
这些数字背后的记录
牵头的论文2
- Identification of Crosstalk Genes Between Primary Sjögren's Syndrome and Primary Biliary Cirrhosis by Transcriptome Analysis.
- Investigating the causal relationship and potential shared diagnostic genes between primary biliary cholangitis and systemic lupus erythematosus using bidirectional Mendelian randomization and transcriptomic analyses.
联系这家医院
出示给工作人员或司机的院名卡
成都大学附属医院
Affiliated Hospital of Chengdu University
成都
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
没有匹配到医院级的 ROR 记录。
Hospital of Chengdu University of Traditional Chinese Medicine; Clinical Medical College & Affiliated Hospital of Chengdu University; Affiliated Zigong TCM Hospital of Chengdu University of TCM; Affiliated Hospital of Chengdu University of TCM; Clincal Medical College & Affiliated Hospital of Chengdu University